IN8bio Revenue and Competitors
Estimated Revenue & Valuation
- IN8bio's estimated annual revenue is currently $5.3M per year.
- IN8bio's estimated revenue per employee is $155,000
Employee Data
- IN8bio has 34 Employees.
- IN8bio grew their employee count by -26% last year.
IN8bio's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Director, President, CEO, and Co-Founder | Reveal Email/Phone |
2 | EVP and Chief Scientific Officer | Reveal Email/Phone |
3 | Associate Director, Accounting | Reveal Email/Phone |
4 | Chairman The Board Directors | Reveal Email/Phone |
5 | Associate Director, Analytical Development | Reveal Email/Phone |
6 | Operations Director | Reveal Email/Phone |
7 | Senior Director, R&D | Reveal Email/Phone |
8 | Director Quality Implementation | Reveal Email/Phone |
9 | Director Quality Operations | Reveal Email/Phone |
10 | Senior Scientist | Reveal Email/Phone |
IN8bio Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.6M | 4 | 0% | N/A | N/A |
#2 | $3.7M | 24 | 41% | $44M | N/A |
#3 | $6.2M | 40 | -7% | N/A | N/A |
#4 | $42M | 271 | -1% | N/A | N/A |
#5 | $12.7M | 82 | 0% | $10M | N/A |
#6 | $2.5M | 16 | 0% | N/A | N/A |
#7 | $7.5M | 45 | 0% | $51.6M | N/A |
#8 | $0.2M | 1 | -50% | N/A | N/A |
#9 | $4.3M | 26 | -16% | $3.3M | N/A |
#10 | $3.7M | 24 | 4% | N/A | N/A |
What Is IN8bio?
IN8bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancer. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems, and can intrinsically differentiate between healthy and diseased tissue. IN8bio develops ex vivo-expanded and activated gamma-delta T cells based upon its deep expertise in gamma-delta T cell biology, proprietary genetic engineering, and cell-type specific manufacturing capabilities, which we refer to collectively as our DeltEx platform. IN8bio’s platform employs allogeneic, autologous, and genetically modified approaches to develop novel cell therapies, which are designed to effectively identify and eradicate tumor cells. IN8bio is currently the most clinically advanced gamma-delta T cell company and the first company to bring genetically modified gamma-delta T cells into the clinic.\n\nFor more information about the Company and its programs, visit www.IN8bio.com.
keywords:N/A
N/A
Total Funding
34
Number of Employees
$5.3M
Revenue (est)
-26%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in New York
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $6.6M | 34 | 17% | $116M |
#2 | $4.1M | 34 | 17% | $6M |
#3 | $7.3M | 34 | -28% | $143.8M |
#4 | $3.9M | 34 | -21% | N/A |
#5 | $3.7M | 34 | 26% | $1.6M |